Sichuan Huiyu Pharmaceutical Co.Ltd(688553)
Prior approval opinions of independent directors
As an independent director of Sichuan Huiyu Pharmaceutical Co.Ltd(688553) (hereinafter referred to as “the company”), we carefully reviewed the relevant proposals to be submitted to the 22nd Meeting of the first board of directors of the company based on independent judgment in accordance with the provisions of Sichuan Huiyu Pharmaceutical Co.Ltd(688553) articles of association and other relevant laws, regulations and normative documents.
1、 Proposal on reappointment of audit institutions in 2022
After examination, we believe that Tianjian Certified Public Accountants (special general partnership) has the audit qualification related to securities and futures business, and has rich experience in providing audit services for listed companies. In the previous audit work, it is diligent and conscientious to perform its audit responsibilities, and objectively, fairly and independently evaluate the company’s financial status and operating results. By the end of 2021, Tianjian Certified Public Accountants (special general partnership) has accrued more than 100 million yuan of occupational risk fund and purchased more than 100 million yuan of occupational insurance. Relevant occupational insurance can cover civil liability caused by audit failure and has the ability to protect investors.
Therefore, we agree to continue to appoint Tianjian Certified Public Accountants (special general partnership) as the audit institution of the company in 2022, and agree to submit the proposal to the 22nd Meeting of the first board of directors for deliberation and voting.
(no text below this page)
(there is no text on this page, which is the signature page of Sichuan Huiyu Pharmaceutical Co.Ltd(688553) independent directors’ prior approval opinions)
Independent director: Wang Ruwei
Independent director: long Yongqiang
Independent director: Liang Xinxin
March 24, 2022
